Clinical research in resource-limited settings
Read our perspective, which includes examples and case studies of how members contribute their expertise and knowledge to expand the clinical research infrastructure in LMICs.
Read more
Read our perspective, which includes examples and case studies of how members contribute their expertise and knowledge to expand the clinical research infrastructure in LMICs.
Read more
The associations representing the global research-based biopharmaceutical industry reaffirm that weakening the intellectual property (IP) framework as proposed in the “Quad compromise” is unnecessary and harmful to innovation. An IP waiver does not address inequitable access to COVID-19 vaccines and will put global health security at risk. It will undermine innovation and industry’s ability to...
Read moreThe WHO Global Influenza Surveillance and Response System (GISRS) celebrates this year its 70th anniversary, marking decades of successful information sharing and collaboration for influenza surveillance, preparedness and response. Its expansion to GISRS+ to include other respiratory pathogens must ensure that influenza surveillance is not deprioritized nor negatively impacted. With regards the EB150 request for...
Read moreCOVID-19 has reminded us that those with chronic conditions and co-morbidities are often the most vulnerable and have suffered the most throughout the pandemic.
Read moreWhile the world is still grappling with COVID-19, the global community needs to look ahead to how it can learn from this experience and better prepare for the next health crisis. Ending this pandemic and preparing for the next one demands an end-to-end, lab-to-last-mile strategy. The world needs to act globally and locally to improve...
Read moreThis news release was originally published by UICC on 20 May 2022. IFPMA and many of its member companies are partners of ATOM Coalition. The ATOM Coalition brings together the most experienced organisations to increase access to quality-assured essential cancer medicines in low- and lower middle-income countries, and to help countries develop the capacity for...
Read moreSwift pathogen surveillance and sharing, an enabling innovation ecosystem, and regulatory agility are among the biopharmaceutical industry’s 10 lessons learned in the process of successfully developing COVID-19 vaccines and treatments. These lessons must be preserved for future ability to fight against unknown diseases. The most important lesson of the report is that we must redouble...
Read moreThis report identifies 10 insights the biopharmaceutical industry has gathered so far as the world moves into the third year of the COVID-19 pandemic.
Read more
As IFPMA members, we believe that the knowledge gained from clinical trials should be used to support the development and use of innovative medicines, vaccines and other therapies, in order to develop the right treatment for the right patient.
Read more
The COVID-19 pandemic has taught us a lot and yet we can still keep learning. While the pandemic has impacted everyone, it has provided a spark for further exploration into how clinical trials should be improved globally.
Read moreThis report highlights a select few collaborations with IFPMA companies, and details the innovative methods in which these collaborations are working to meet urgent global supply needs.
Read more
A number of global health stakeholders are asserting that the supply of COVID-19 therapeutics is a challenge globally, and that industry is largely responsible for this.
Read more